MedPath

Cinclus Pharma Gains FDA Agreement on Pediatric Study Plan for Linaprazan Glurate

  • Cinclus Pharma reached an agreement with the FDA on its initial Pediatric Study Plan (iPSP) for linaprazan glurate, a crucial step for potential market approval in the US.
  • The agreed iPSP includes a clinical efficacy and safety trial involving approximately 100 pediatric patients, mirroring the treatment schedule used in adult Phase III trials.
  • This regulatory milestone, similar to an agreement with the EMA, advances linaprazan glurate towards addressing unmet needs in both adult and pediatric populations with acid-related diseases.
  • An approved pediatric indication would significantly expand the target population for linaprazan glurate, highlighting its potential impact on treating gastroesophageal reflux disease (GERD).
Cinclus Pharma has announced an agreement with the U.S. Food and Drug Administration (FDA) regarding its initial Pediatric Study Plan (iPSP) for linaprazan glurate. This agreement is a regulatory prerequisite for market approval of linaprazan glurate, a drug aimed at treating acid-related diseases, in adult patients. Furthermore, it opens the possibility of expanding the drug's approval for use in children.
Christer Ahlberg, CEO of Cinclus Pharma, stated, "The agreement on our pediatric study plan with the FDA is a prerequisite for market approval in the US, so it’s really a milestone... Furthermore, an approved pediatric indication would significantly increase the target population for linaprazan glurate."

Pediatric Study Plan Details

The agreed iPSP primarily involves a clinical efficacy and safety trial. This trial will include approximately 100 pediatric patients who will receive linaprazan glurate following the same treatment schedule as used in the company's Phase III trials for adult patients with erosive gastroesophageal reflux disease (eGERD). The study plan closely mirrors the agreement recently reached with the European Medicines Agency (EMA) Pediatric Committee (PDCO).

Regulatory Context

A regulatory agreement on a pediatric study plan is mandatory before a sponsor can submit a Marketing Authorization Application for commercializing a new medicine for adult patients. Cinclus Pharma submitted its proposed iPSP to the FDA in December 2023 and has since been navigating the regulatory review process. The agreed iPSP includes a deferral, allowing the pediatric efficacy and safety trial to be conducted after the Marketing Authorization Application has been submitted.

About Linaprazan Glurate

Linaprazan glurate, a prodrug of P-CAB linaprazan initially developed by AstraZeneca, is Cinclus Pharma's leading drug candidate. It is designed for treating acid-related diseases and disorders of the upper gastrointestinal tract. Linaprazan glurate aims to more effectively heal erosions in the esophageal mucosa and alleviate symptoms of gastroesophageal reflux disease (GERD) compared to existing treatments like proton pump inhibitors (PPIs). Clinical data from over 30 Phase I and two Phase II studies, involving more than 3,000 participants, support the safety and efficacy of linaprazan and linaprazan glurate. Phase III studies are planned to commence in 2025. GERD affects approximately 133 million adults in the US and EU, with about 10 million patients suffering from the most severe forms, highlighting the need for new and improved treatments.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Pharming's Leniolisib Shows Positive Phase 3 Data in Young Children with APDS

- Pharming's leniolisib demonstrated positive topline results in a Phase 3 trial for children aged 4-11 with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
- The study showed improvements in lymphoproliferation and immunophenotype correction, consistent with results from trials in older patients.

Arrowhead Submits FDA Application for Plozasiran in Familial Chylomicronemia Syndrome

- Arrowhead Pharmaceuticals has submitted a new drug application to the FDA for plozasiran for the treatment of familial chylomicronemia syndrome (FCS).
- Plozasiran demonstrated sustained reductions in apolipoprotein C-III and triglycerides in the PALISADE Phase 3 study and open-label extensions.

Arrowhead Submits Plozasiran NDA to FDA for Familial Chylomicronemia Syndrome

- Arrowhead Pharmaceuticals has submitted an NDA to the FDA for plozasiran, targeting familial chylomicronemia syndrome (FCS), a rare genetic disease with no approved treatments.
- The NDA is based on positive Phase 3 PALISADE study results, which showed significant reductions in triglycerides, apolipoprotein C-III, and acute pancreatitis incidence.

Cinclus Pharma Reaches Agreement with EMA on Pediatric Study Plan for Linaprazan Glurate

- Cinclus Pharma has reached an agreement with the European Medicines Agency (EMA) regarding a pediatric study plan for linaprazan glurate, a drug intended for adult patients.
- The agreement with the EMA is a prerequisite for obtaining marketing authorization in the EU for medicines aimed at adult populations.

FDA Grants Priority Review to Telix's Pixclara for Glioma Imaging

- The FDA has accepted the New Drug Application for TLX101-CDx (Pixclara), a PET imaging agent for glioma, granting it priority review.
- Pixclara targets amino acid transporters in brain tumors and aims to improve diagnostic accuracy in differentiating tumor progression from treatment-related changes.

Cinclus Pharma Reaches Agreement with EMA on Pediatric Investigation Plan for Linaprazan Glurate

- Cinclus Pharma has reached an agreement with the EMA on a Pediatric Investigation Plan (PIP) for linaprazan glurate, a key step for potential marketing approval in the EU.
- The PIP includes a clinical efficacy and safety trial involving approximately 100 pediatric patients, mirroring the treatment schedule used in adult Phase III trials.

Cinclus Pharma Achieves EMA Agreement on Pediatric Investigation Plan for Linaprazan Glurate

- Cinclus Pharma has reached an agreement with the EMA on its Pediatric Investigation Plan (PIP) for linaprazan glurate, a key step toward potential marketing approval in the EU.
- The agreed PIP includes a clinical efficacy and safety trial involving approximately 100 pediatric patients, mirroring the treatment schedule used in adult Phase III trials.

Cinclus Pharma Achieves Agreement with EMA on Pediatric Investigation Plan for Linaprazan Glurate

- Cinclus Pharma has reached an agreement with the EMA's Paediatric Committee (PDCO) on its Pediatric Investigation Plan (PIP) for linaprazan glurate.
- The agreed PIP includes a clinical efficacy and safety trial involving approximately 100 pediatric patients, mirroring the treatment schedule used in adult Phase III trials.

FDA Grants Priority Review to Telix's Pixclara for Glioma Imaging

- The FDA has accepted Telix Pharmaceuticals' New Drug Application for TLX101-CDx (Pixclara), a PET imaging agent for glioma, granting priority review.
- Pixclara, also known as 18F-FET, aims to improve the characterization of progressive or recurrent glioma in both adult and pediatric patients.

FDA Expands Brineura Approval to Include All Ages with CLN2 Disease

- The FDA has approved BioMarin's sBLA for Brineura, extending its use to children of all ages with CLN2 disease, regardless of symptom onset.
- Study 190-203 demonstrated that Brineura slowed motor function decline and delayed disease onset in children under 3 years of age with CLN2 disease.

Reference News

[1]
Cinclus Pharma agrees on pediatric study plan with FDA | Placera
placera.se · Nov 22, 2024

Cinclus Pharma reached an agreement with the FDA on its Pediatric Study Plan (iPSP), a prerequisite for market approval ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy